Differentiation of Pluripotent Stem Cells to Form Renal Organoids

    公开(公告)号:US20250075188A1

    公开(公告)日:2025-03-06

    申请号:US18899875

    申请日:2024-09-27

    Abstract: A method is provided for producing renal organoids comprising nephrons, ureteric bud and vasculature and/or progenitors of these. In one embodiment, the methods includes contacting intermediate mesoderm cells with: fibroblast growth factor 9 and/or fibroblast growth factor 20 and/or fibroblast growth factor 2 and optionally, one or more selected from the group consisting of: bone morphogenic protein 7; heparin; a Wnt agonist; retinoic acid; and an RA antagonist under conditions that promote formation of vascularized renal organoids. Another embodiment includes producing mesoderm cells by sequentially contacting pluripotent stem cells with a Wnt agonist and fibroblast growth factor 9 and/or fibroblast growth factor 20 and/or fibroblast growth factor 2, followed by a relatively short re-exposure to the Wnt agonist. The renal organoids may have end uses such as for kidney repair and regeneration, bioprinting of kidneys or functional components thereof, renal cell arrays and screening compounds for nephrotoxicity.

    HISTONE DEACETYLASE INHIBITORS
    5.
    发明公开

    公开(公告)号:US20240109847A1

    公开(公告)日:2024-04-04

    申请号:US18259052

    申请日:2021-12-23

    CPC classification number: C07D239/91 C07D231/56

    Abstract: The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for inhibiting Class IIa versus Class I HDACs. The present application also relates to methods of using the compounds and to uses of the compounds, especially in relation to the prevention of a disease, disorder or condition associated with Class IIa HDAC activity. In one form, the compounds are (ortho-phenyl) phenyl hydroxamates. In another form, the compounds are as provided in Formula (I), wherein R1 is a phenyl or cycloalkenyl which may be optionally substituted. Formula (I)

    DETECTION METHOD
    7.
    发明公开
    DETECTION METHOD 审中-公开

    公开(公告)号:US20240027346A1

    公开(公告)日:2024-01-25

    申请号:US18253308

    申请日:2021-11-17

    Abstract: The disclosure relates to a method for detecting a nerve agent in an analyte, said nerve agent having a phosphorus-fluorine bond, which method comprises: (a) contacting the analyte with a solid state composition comprising a sensor compound; wherein the sensor compound comprises a basic nitrogen atom and a hydroxyaryl moiety protected by a silyl protecting group; and wherein, in the presence of hydrogen fluoride, said silyl group is cleaved to effect deprotection of the hydroxyl group thus forming a luminescent reporter compound; (b) irradiating the solid state composition at a predetermined wavelength; (c) measuring the luminescence to determine if the reporter compound is present; and (d) determining whether the nerve agent is present in the analyte based on the measurement obtained in step (c).

    DE-AERATING FROTH PRODUCTS
    10.
    发明申请

    公开(公告)号:US20230091569A1

    公开(公告)日:2023-03-23

    申请号:US17795824

    申请日:2021-01-27

    Abstract: An apparatus (40) for deaerating a froth comprising a spinning basket (44) mounted on a driven shaft (46). The side walls of the spinning basket have a mesh or openings therein. Froth is supplied to the interior of the spinning basket and contacts the floor of the spinning basket and is flung outwardly through the mesh or openings to break the bubbles and deaerate the froth. A solid all (42) may surround the spinning basket to further assist in deaeration. A spinning plate may be used in place of the spinning basket. In another embodiment, vacuum is used to deaerate the froth.

Patent Agency Ranking